
PRICEWATERHOUSE COPERS @



Conducting Compliance Assessments and Building Internal Controls In Pharmaceutical R&D

Third Annual Medical Research Summit – Session 2.01
Michael Swiatocha
March 6, 2003

Agenda

- Introduction to Compliance
- Traditional Compliance Assessments
- Enterprise Wide Risk Management (EWRM) in R&D
- Risk Assessment Approach
- Pharmaceutical Case Study
- Questions & Answers

Compliance Program


A compliance program is a management process comprised of formal reporting structures and risk mitigation systems designed to motivate, measure, and monitor an organization's legal and ethical performance around complex business practices.

Seven Elements of a Compliance Program

- Standards & Procedures
- Oversight Responsibility
- Education & Training
- Lines of Communication
- Monitoring & Auditing
- Enforcement & Discipline
- Response & Prevention

Compliance Programs Address All Components of the Value Chain

Pharmaceutical & Medical Products Value Chain



Transitioning from Traditional Compliance Programs

- Standards & Procedures
- Oversight Responsibility
- Education & Training
- Lines of Communication
- Monitoring & Auditing
- Enforcement & Discipline
- Response & Prevention

QAU
Internal Audit
EWRM

Enterprise Wide Risk Management

- Best in class organizations are embedding their compliance programs into an expanded view of enterprise wide risk management (EWRM)
- Compliance transitions from a reactive, process intensive activity to a dynamic program enabling the organization to manage a broad range of changes that can impact its performance
- EWRM defines risks as events or activities that can affect the achievement of an organization's goals
- EWRM addresses all organizational goals, objectives and relationships with key stakeholders including R&D
- EWRM is an anticipatory, proactive process that becomes a key part of strategy and planning. EWRM helps mitigate surprises and ensures all organizations are aligned with key objectives

Enterprise Wide Risk Management



Risk Assessments

- Potential Impact of Risk
- Probability
- Primary Exposure
- Control Mechanisms
- Accountability

Rating the Potential Impact of Risk

- The <u>Impact</u> on financial, operational and/or legal implications can be considered as well as the ability to achieve the stated objective in the face of that risk.
 - Low if the impact of the risk would have some financial, operational and/or legal implications and require attention, but is no greater than an irritant to the organization
 - Medium if the impact of the risk would have significant financial, operational and/or legal implications, and/or would significantly delay the ability to achieve the objectives or otherwise affect it
 - ➤ High if the impact of the risk would have major financial, operational and/or legal implications and/or it is so significant one would need to abandon the objectives

Rating the Probability of Occurrence

- For rating the <u>Probability</u> of risks, the frequency of historical events can be considered as well as current outlook.
 - Low occurrence is unlikely
 - Medium occurrence is somewhat likely
 - High occurrence is very likely

Identifying the Primary Exposures

- Identify the <u>Primary Exposure</u> to indicate the direct exposure facing an organization using categories such as:
 - Government Enforcement
 - Regulatory Violation
 - Financial Loss
 - Reputational Damage
 - Failure to comply with internal policy
 - Inefficiencies and/or excessive costs
 - Inappropriate financial reporting or disclosure
 - Legal Risk

Control Mechanisms

- For all risks with a high composite rating for impact and probability, existing <u>Control Mechanisms</u> should be considered. An organization's management should apply a rating corresponding to the level of control, such as the following:
 - Policies and procedures exist and are tested as part of external or internal audits, and/or monitoring controls are in place
 - Policies and procedures exist
 - Policies and procedures are in the early stages of development
 - Policies and procedures do not exist

Accountability

Pharmaceutical Case Study

Functional Areas	# of Risks Identified	# of "High" Risks Identified	# of "High" Risks Identified w/Limited Controls in Place
Sales & Marketing	22	14	8
R&D	44	12	3
Manufacturing	45	5	1
Regulatory Affairs	26	6	1
Financial Reporting	15	8	0
HR	42	12	2
IT	8	6	2
International	16	8	2

For more information, contact

Michael P. Swiatocha
Director, Client Services
PricewaterhouseCoopers, LLP
400 Campus Drive
Florham Park, NJ 07932
973-236-4541

michael.p.swiatocha@us.pwcglobal.com

